Servier licenses GLPG1972 in osteoarthritis from Galapagos
(Thomson Reuters ONE) -
Mechelen, Belgium; Suresnes Cedex, France; 27 July 2017, 22.00 CET, regulated
information - As a result of their research collaboration, Servier announces
today that it has exercised its option to develop novel osteoarthritis molecule
GLPG1972/S201086 from Galapagos NV (Euronext/NASDAQ: GLPG), thus obtaining
global commercial rights outside the U.S.
Osteoarthritis (OA) is a highly prevalent and disabling pathology, considered as
a priority by the World Health Organization. So far, no treatment is available
to counteract disease progression, patients being left with only symptomatic
treatments. OA represents an important unmet medical need. Since June 2010,
Servier and Galapagos have been joining their expertise to tackle this problem,
leading to the development of GLPG1972/S201086, a first-in-class and potentially
disease-modifying molecule.
The mechanism of action of GLPG1972/S201086, which targets a cartilage degrading
enzyme called ADAMTS-5, has been confirmed in two animal models. The phase 1
trial run by Galapagos met all its safety and pharmacokinetic targets. Phase 1
in healthy volunteers also demonstrated that GLPG1972/S201086 reduced ARGS
neoepitope, an important cartilage breakdown biomarker, by more than 50% within
two weeks. Galapagos is currently exploring safety and pharmacokinetics of
G1972/S201086 in a phase 1b trial in OA patients in the US. A Phase 2 program is
currently being prepared with this drug candidate.
"We strongly believe that the combination of our knowledge of osteoarthritis
with Galapagos' recognized expertise in discovery of small molecules with novel
modes of potentially increases chances to deliver life-changing treatments to
patients", said Dr. Patricia Belissa-Mathiot, Director of the Research and
development in immune-inflammatory disease for Servier.
"We look forward to exploring together how GLPG1972/S201086 might meet OA
patients' urgent needs. Servier's commitment in OA fits really well with our
drive to deliver a first disease-modifying drug in this debilitating disease,"
said Dr. Piet Wigerinck, Chief Scientific Officer of Galapagos.
Galapagos will receive a ?6 million license fee from Servier and is eligible to
a total of ?290 million in success-based milestones from the collaboration.
Servier and Galapagos will make joint decisions on the development through a
joint steering committee. Galapagos has full US commercial rights to
GLPG1972/S201086 and is entitled to receive royalties on commercial sales
outside the US.
About Servier
Servier is an international pharmaceutical company governed by a non-profit
foundation, with its headquarters in France (Suresnes). With a strong
international presence in 148 countries and a turnover of 4 billion euros in
2016, Servier employs 21,000 people worldwide. Entirely independent, the Group
reinvests 25% of its turnover (excluding generic drugs) in research and
development and uses all its profits for development. Corporate growth is driven
by Servier's constant search for innovation in five areas of excellence:
cardiovascular, immune-inflammatory and neuropsychiatric disease, oncology and
diabetes, as well as by its activities in high-quality generic drugs.
Becoming a key player in the fight against immune-inflammatory disease is part
of Servier's long-term strategy. Servier wishes to bring innovative therapeutic
solutions to patients suffering from these often highly debilitating
pathologies. Its research focuses on lupus, Gougerot-Sjögren syndrome and
scleroderma, for which no cure exists. This goal will be reached by establishing
partnerships all over the world, in order to accelerate the marketing of
innovative drugs with high added value for patients.
More information: www.servier.com
About Galapagos
Galapagos (Euronext & NASDAQ: GLPG) is a clinical-stage biotechnology company
specialized in the discovery and development of small molecule medicines with
novel modes of action. Our pipeline comprises a pipeline of Phase 3, Phase 2,
Phase 1, pre-clinical, and discovery programs in cystic fibrosis, inflammation,
fibrosis, osteoarthritis and other indications. We have discovered and developed
filgotinib: in collaboration with Gilead we aim to bring this JAK1-selective
inhibitor for inflammatory indications to patients all over the world. Galapagos
is focused on the development and commercialization of novel medicines that will
improve people's lives. The Galapagos group, including fee-for-service
subsidiary Fidelta, has approximately 550 employees, operating from its
Mechelen, Belgium headquarters and facilities in The Netherlands, France, and
Croatia. More information at www.glpg.com.
Contact Servier
Karine Bousseau
Servier External Communications
Tel: +33 1 5572 4021 /+33 6.49.92.16.05
media(at)servier.com
Contact Galapagos
Investors:
Elizabeth Goodwin
VP IR & Corporate Communications
+1 781 460 1784
Paul van der Horst
Director IR & Business Development
+31 6 53 725 199
ir(at)glpg.com
Media:
Evelyn Fox
Director Communications
+31 6 53 591 999
communications(at)glpg.com
This press release contains inside information with respect to Galapagos within
the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the
Council of 16 April 2014 on market abuse (market abuse regulation).
Galapagos forward-looking statements
This release may contain forward-looking statements, including, among other
things, statements regarding the mechanism of action and profile of, and timing
and results of clinical trials with, GLPG1972. Galapagos cautions the reader
that forward-looking statements are not guarantees of future performance.
Forward-looking statements involve known and unknown risks, uncertainties and
other factors which might cause the actual results, financial condition and
liquidity, performance or achievements of Galapagos, or industry results, to be
materially different from any historic or future results, financial conditions
and liquidity, performance or achievements expressed or implied by such forward-
looking statements. In addition, even if Galapagos' results, performance,
financial condition and liquidity, and the development of the industry in which
it operates are consistent with such forward-looking statements, they may not be
predictive of results or developments in future periods. Among the factors that
may result in differences are that Galapagos' expectations regarding its
GLPG1972 development program may be incorrect, the inherent uncertainties
associated with competitive developments, clinical trial and product development
activities and regulatory approval requirements (including that data from the
ongoing clinical research programs may not support registration or further
development of GLPG1972 due to safety, efficacy or other reasons), Galapagos'
reliance on collaborations with third parties (including its collaboration
partner for osteoarthritis Servier), and estimating the commercial potential of
Galapagos' product candidates. A further list and description of these risks,
uncertainties and other risks can be found in Galapagos' Securities and Exchange
Commission (SEC) filings and reports, including in Galapagos' most recent annual
report on form 20F-F filed with the SEC and other filings and reports filed by
Galapagos with the SEC. Given these uncertainties, the reader is advised not to
place any undue reliance on such forward-looking statements. These forward-
looking statements speak only as of the date of publication of this document.
Galapagos expressly disclaims any obligation to update any such forward-looking
statements in this document to reflect any change in its expectations with
regard thereto or any change in events, conditions or circumstances on which any
such statement is based or that may affect the likelihood that actual results
will differ from those set forth in the forward-looking statements, unless
specifically required by law or regulation.
Servier licenses GLPG1972 in osteoarthritis:
http://hugin.info/133350/R/2123848/810272.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Galapagos NV via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 27.07.2017 - 22:00 Uhr
Sprache: Deutsch
News-ID 554325
Anzahl Zeichen: 9602
contact information:
Town:
Mechelen
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 231 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Servier licenses GLPG1972 in osteoarthritis from Galapagos"
steht unter der journalistisch-redaktionellen Verantwortung von
Galapagos NV (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
